Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2024-02-20 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ASTRAZENECA COMPLETES ACQUISITION OF ICOSAVAX
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content primarily announces the completion of the acquisition of Icosavax, including details about the transaction, the acquired company's business, and forward-looking statements. It also mentions that Icosavax shares will be delisted from Nasdaq and that Icosavax will terminate its registration under the Exchange Act. The document is not a full annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing reporting a significant corporate event (acquisition completion and related delisting). Given the nature of the content and the form type (6-K), this fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories. The document length (12,457 characters) and detailed content confirm it is not a mere announcement of a report publication but a substantive filing. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-02-20 English
TAGRISSO PLUS CHEMO APPROVED IN US FOR LUNG CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the FDA approval of Tagrisso plus chemotherapy for lung cancer, including clinical trial results, regulatory review status, and company background. The document is informational and regulatory in nature, reporting a significant corporate event but does not contain financial statements or detailed financial performance data. It is not an annual or interim report, earnings release, or management discussion. The Form 6-K is a regulatory filing used by foreign companies to report material information to the SEC. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (over 14,000 characters) and content confirm it is a substantive regulatory announcement rather than a brief report publication announcement or a certification.
2024-02-20 English
FDA ACCEPTS DATO-DXD BLA FOR NONSQUAMOUS NSCLC
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides an update on the FDA acceptance of a Biologics License Application (BLA) for a drug (Dato-DXd) for nonsquamous non-small cell lung cancer. The document includes detailed information about the drug, clinical trial results, regulatory status, and company background. It is not a full annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory announcement providing material information about a significant regulatory milestone. Form 6-K filings are typically classified as Regulatory Filings (RNS) because they are periodic reports submitted by foreign private issuers to the SEC to disclose material information. The document is over 12,000 characters and contains substantive information but is not a financial report or detailed management report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-02-20 English
TAGRISSO IMPROVED PFS IN STAGE III LUNG CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed clinical trial results and updates on the Tagrisso drug for lung cancer, including trial design, efficacy, safety, and ongoing research. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about clinical trial results and drug development progress. The document is lengthy (11,994 characters) and contains substantive information, not just an announcement or certification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-02-20 English
AstraZeneca PLC Annual Report & 20-F Information 2023
Annual Report (ESEF) Classification · 100% confidence FY 2023
2024-02-20 English
AstraZeneca PLC Annual Report & 20-F Information 2023
Annual Report Classification · 100% confidence The document is explicitly titled 'AstraZeneca PLC Annual Report and Form 20-F Information 2023'. It contains comprehensive sections including a Strategic Report, Corporate Governance, Financial Statements, and detailed financial tables for the fiscal year. It is a full-length annual report rather than an announcement or a summary, fitting the definition of a 10-K/Annual Report. FY 2023
2024-02-20 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.